Gene therapy for Leber Congenital Amaurosis Type 16

Hubble Therapeutics is focused on developing innovative gene therapies aimed at transforming healthcare for patients diagnosed with LCA16, a rare genetic condition that affects vision. Their approach leverages advanced scientific techniques to preserve and enhance functional sight, providing patients with new opportunities to experience life more fully. By harnessing the power of gene therapy, Hubble Therapeutics aims to address the underlying genetic causes of LCA16, potentially offering a long-term solution for those affected by this condition.

The company is dedicated to creating novel gene therapies that not only target the specific genetic mutations associated with LCA16 but also aim to improve overall visual function. This commitment to advancing therapeutic options reflects Hubble Therapeutics' mission to open new windows of possibility for patients, ultimately enhancing their quality of life through cutting-edge scientific advancements in the field of gene therapy.

United States

Developing a gene therapy for Leber Congenital Amaurosis Type 16

Eye Diseases

Hubble Therapeutics

Company Details